Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Ferlay, Hai-rim Shin, F. Bray, D. Forman, C. Mathers, D. Parkin (2010)
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 127
A. Benson, T. Bekaii-Saab, E. Chan, Yi-Jen Chen, M. Choti, H. Cooper, P. Engstrom, P. Enzinger, M. Fakih, M. Fenton, C. Fuchs, J. Grem, S. Hunt, A. Kamel, L. Leong, E. Lin, K. May, M. Mulcahy, K. Murphy, E. Rohren, D. Ryan, L. Saltz, Sunil Sharma, D. Shibata, J. Skibber, W. Small, C. Sofocleous, A. Venook, C. Willett, K. Gregory, Deborah Freedman-Cass (2013)
Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines.Journal of the National Comprehensive Cancer Network : JNCCN, 11 2
M. Conron, S. Phuah, Daniel Steinfort, E. Dabscheck, G. Wright, D. Hart (2007)
Analysis of multidisciplinary lung cancer practiceInternal Medicine Journal, 37
National Comprehensive Cancer Network
NCCN Guidelines
Bouchardy C, Rapiti E, Blagojevic S
Older female cancer patients: Importance, causes, and consequences of undertreatment
Sean Bydder, Anna Nowak, K. Marion, Michael Phillips, R. Atun (2009)
The impact of case discussion at a multidisciplinary team meeting on the treatment and survival of patients with inoperable non‐small cell lung cancerInternal Medicine Journal, 39
Jonker DJ, O'Callaghan CJ, Karapetis CS
Cetuximab for the treatment of colorectal cancer
K. Ung, B. Campbell, D. Duplan, D. Ball, S. David (2016)
Impact of the lung oncology multidisciplinary team meetings on the management of patients with cancerAsia‐Pacific Journal of Clinical Oncology, 12
Schonberg MA, Marcantonio ER, Ngo L
Causes of death and relative survival of older women after a breast cancer diagnosis
Au HJ, Mulder KE, Fields AL
Systematic review of management of colorectal cancer in elderly patients
R. Audisio, D. Papamichael (2012)
Treatment of colorectal cancer in older patientsNature Reviews Gastroenterology &Hepatology, 9
Benson AB III, Bekaii-Saab T, Chan E
Metastatic colon cancer, version 3
Somashekhar SP KR, Rauthan A
Double blinded validation study to assess performance of IBM artificial intelligence platform, Watson for Oncology in comparison with Manipal multidisciplinary tumour board-First study of 638 breast cancer cases
Kuebler JP, Wieand HS, O'Connell MJ
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07
Alper BS, Hand JA, Elliott SG
How much effort is needed to keep up with the literature relevant for primary care
R. Yancik, M. Wesley, L. Ries, R. Havlik, B. Edwards, Jerome Yates (2001)
Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older.JAMA, 285 7
Lutterbach J, Pagenstecher A, Spreer J
The brain tumor board: Lessons to be learned from an interdisciplinary conference
N. Epstein (2014)
Multidisciplinary in-hospital teams improve patient outcomes: A reviewSurgical Neurology International, 5
A. Seidman, M. Pilewskie, M. Robson, J. Kelvin, M. Zauderer, A. Epstein, M. Kris, Julia Fu, Jeffrey Keesing, Aryeh Caroline, Mark Megerian, J. EggebraatenThomas, R. Delima, Setnes Louise, K. Barker, A. Gucalp (2015)
Integration of multi-modality treatment planning for early stage breast cancer (BC) into Watson for Oncology, a Decision Support System: Seeing the forest and the trees.Journal of Clinical Oncology, 33
Z. Kordatou, P. Kountourakis, D. Papamichael (2014)
Treatment of older patients with colorectal cancer: a perspective reviewTherapeutic Advances in Medical Oncology, 6
Suwanvecho S, Suwanrusme H, Sangtian M
Concordance assessment of a cognitive computing system in Thailand
Yothers G, O'Connell MJ, Allegra CJ
Oxaliplatin as adjuvant therapy for colon cancer: Updated results of NSABP C-07 trial, including survival and subset analyses
Kopetz S, Chang GJ, Overman MJ
Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy
G. Palmer, A. Martling, B. Cedermark, T. Holm (2011)
Preoperative tumour staging with multidisciplinary team assessment improves the outcome in locally advanced primary rectal cancerColorectal Disease, 13
Wolmark N, Rockette H, Fisher B
The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project protocol C-03
C. Allemani, H. Storm, A. Voogd, K. Holli, I. Izarzugaza, A. Torrella‐Ramos, M. Bielska-Lasota, T. Aareleid, E. Ardanaz, M. Colonna, E. Crocetti, A. Danzon, M. Federico, I. Garau, P. Grosclaude, G. Hédelin, C. Martínez-García, K. Peignaux, I. Pleško, M. Primic‐Žakelj, J. Rachtan, G. Tagliabue, R. Tumino, A. Traina, L. Tryggvadottir, M. Vercelli, M. Sant (2010)
Variation in 'standard care' for breast cancer across Europe: a EUROCARE-3 high resolution study.European journal of cancer, 46 9
Purpose: IBM Watson for Oncology (WFO) is a clinical decision-support computing system that provides oncologists with evidence-based treatment recommendations for a variety of cancer diagnoses. The evidence-based supported treatment recommendations are presented in three categories: Recommended, representing the Memorial Sloan Kettering Cancer Center (MSKCC) preferred approach; For Consideration, evidence-based alternative treatments; and Not Recommended, alternative therapies that may be unacceptable. We examined the absolute concordance of treatment options with that of the recommendations of a multidisciplinary team of oncologists from Gachon University, Gil Medical Centre, Incheon, South Korea. Methods: We enrolled 656 patients with stage II, III, and IV colon cancer between 2009 and 2016. Cases were processed using WFO and, using retrospective clinical data, outputs were compared with the actual treatment the patient received. Absolute concordance was defined as an alignment of recommendation in the Recommended MSKCC preferred-approach category. Treatment recommendations that were represented in the For Consideration category were not the focus of this study. Results: The absolute concordance between the WFO-derived MSKCC preferred approach and Gil Medical Centre treatment recommendations was 48.9%. The percentage of cases found to be acceptable was 65.8% (432 of 656) and the stage-specific concordance rate was 32.5% for patients with stage II disease who had risk factors and 58.8% for patients with stage III disease. Patients 70 years of age and older had a concordance rate of only 20.2%, whereas younger patients had a concordance rate of 63.8% (P = .0001). Conclusion: The main reasons attributed to the low concordance rate were age, reimbursement plan, omitting chemotherapy after liver resection, and not recommending biologic agents (ie, cetuximab and bevacizumab).
JCO Clinical Cancer Informatics – Wolters Kluwer Health
Published: Apr 3, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.